Conclusions
1 evidence topic · 4 sources
Summary
The phase 3 evidence supports an effect on pulmonary gas transfer at 24 weeks. Savara’s August 2026 update continued to identify MOLBREEVI as unapproved, with regulatory applications under review. The reported November 22, 2026 FDA target action date is not an approval date. The clinical results and the available horizon-scan cost estimate do not establish a product-specific budget impact.